COVID-19 Reactivates Anelloviridae in 1,154 Hospitalized Patients, Strongly Tied to Long COVID in Multi-Site Nature Study

Researchers at Boston Children's Hospital and 14 collaborating institutions tracked 1,154 patients using genomic sequencing on over 200,000 samples collected over one year. They detected reactivation of Epstein-Barr, CMV, herpes simplex 1, and especially Anelloviridae, a virus present in 90 percent of adults. The design was a prospective biomarker cohort study funded by NIH, allowing temporal tracking of viral reads against clinical outcomes rather than relying on retrospective serology.

Inflammation, not immunosuppression, drove EBV and CMV reactivation according to blood cytokine patterns, overturning the common assumption that these viruses flare mainly when T-cell control collapses. Anelloviridae reactivation stood out as an independent predictor of persistent physical impairment at follow-up, suggesting a direct contribution to long COVID mechanisms beyond acute SARS-CoV-2 damage.

The findings connect to earlier smaller studies in Nature Medicine 2022 and Cell Reports Medicine 2023 that first hinted at herpesvirus reactivation in severe COVID but lacked the sample size and longitudinal power to link specific viruses to disability. Current data imply that screening for Anelloviridae load during acute illness could identify patients who need targeted antiviral or anti-inflammatory interventions.

Next steps include testing whether early suppression of reactivated viruses reduces long COVID incidence in a planned randomized trial at the same network, with results expected within 18 months.